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Citrullinaemia is a urea cycle defect that results from a deﬁciency of the enzyme arginosuccinate synthetase. Type 1 disease is
diagnosed in childhood, whereas Type 2 disease is adult onset. We report the outcome of a patient with citrullinemia Type 2 who
received a liver transplant at our center and the implications of this diagnosis in liver transplantation.
1.Introduction
Citrullinaemia is a urea cycle defect that results from a
deﬁciency of the enzyme arginosuccinate synthetase. Type 1
disease is diagnosed in childhood, whereas Type 2 disease is
adult onset. We report the outcome of a patient with citru-
llinemia.
2.CaseReport
Our patient was 25 years old when she migrated to our
country from China. Her medical and childhood history was
scant although both the patient and her mother insist these
were uneventful and that she had been an average student
in school. The patient presented to our hospital at the age
of 28 years old for seizures and altered behaviour. She was
described by her husband to be responding slowly when
spoken to. These episodes were interspersed by verbal and
physical aggression, violent outbursts, or hypersomnolence
(sleeping for >24 hours) with urinary incontinence. Com-
puted tomography (CT) and magnetic resonance imaging
(MRI) of the head were normal. Electroencephalography
performed during episodes of hypersomnolence was com-
patiblewithglobalmoderatediﬀuseencephalopathy.Arterial
ammonia (195mmol/L) andlactate (4.5mmol/L)levelswere
markedly elevated. However, other liver tests and imaging
were not suggestive of liver cirrhosis and excluded the pres-
ence of any portosystemic shunt. CT imaging revealed
an atrophic pancreas. Tests for hepatitis B, hepatitis C,
HIV, Wilson disease, systemic autoimmune disease, and
syphilis were negative. In view of her signiﬁcant behavioural
change and elevated ammonia levels, she was screened for
inborn errors of metabolism. Citrulline levels in the blood
(939umol/L) and urine (19.6umol/mmol) were elevated
15-fold and 5-fold, respectively. There was corresponding
elevated plasma arginine and threonine:serine ratios. She
was commenced on L-arginine 1g QDS and high-dose
lactulose therapy which reduced the frequency of her violent
outbursts and reduced the hypersomnolent episodes to once
per fortnight. However, these episodes became increasingly
diﬃcult to control despite L-arginine replacement. By 2009,
she was encephalopathic/hypersomnolent as often as 3 to
4 times per week. The frequency and nature of these
episodes also made drug compliance diﬃcult and aﬀected
her daily activities. Orthotopic liver transplantation (LT)
from a deceased donor was performed in January 2010.
The explanted liver was slightly enlarged measuring 21 ×
16 × 7.5cm and weighed 1.036kg. The gross cut sections
appeared pale brown, and the liver emitted a peculiar
sweetish odour (Figure 1). Histology showed regenerative
changes with alternating atrophied and hyperplastic liver
plates. Mild lobular inﬂammation with ballooning change in
thehepatocyteswasdemonstrated.Nosigniﬁcant steatosisor2 Journal of Transplantation
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Figure 1: Gross specimen of explanted liver.
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Figure 2: Histomicrograph of explanted liver.
ﬁbrosis was seen (Figure 2). Immunosuppression consisted
of prednisolone, tacrolimus, and mycophenolate mofetil.
She has recovered well after LT, without further episodes of
encephalopathy/hypersomnolence despite a normal protein
diet. Arterial ammonia levels (23umol/L) normalised less
than 2 weeks after LT. As her sensorium and ammonia levels
had returned to normal and she was able to function in the
mental capacity of a normal healthy person, citrulline levels
and excretion were not measured again after transplant. She
is currently on tailing doses of dual immunosuppression
(tacrolimus and mycophenolate mofetil). She continues to
remain well more than 1 year after LT and has since returned
to work.
3.Discussion
Citrullinaemia is a urea cycle defect that results from a
deﬁciency of the enzyme arginosuccinate synthetase (ASS).
Nitrogen from enteral sources (dietary protein) and muscle
is excreted from the body, as urea, via the urea cycle. Two
moles of nitrogen (1 from ammonia, 1 from aspartate) are
converted to urea in each cycle. ASS converts citrulline to
arginosuccinic acid in the urea cycle, removing ammonia in
the process. Deﬁciency of ASS results in citrullinaemia, an
autosomal recessive disorder.
The severity of disease and clinical presentation is pro-
portionate to residual enzyme activity, dietary protein load,
and patient age.
3.1. Citrullinaemia Type I (CTLN1). Is the classical form of
ASS deﬁciency, where ASS is deﬁcient in all tissues. In severe
forms, newborns present with hyperammonaemia, vomit-
ing, feeding diﬃculties, and seizures soon after birth. In
milder disease, patients may present later with mild clinical
symptoms or remain asymptomatic in the early neonatal
period or infancy. Untreated newborns or infants universally
develop cerebral oedema. Morbidity and mortality are high.
In one study of newborns, although the 10-year survival
rate was 72%, survivors had mental retardation and growth
impairments [1].
3.2. Citrullinaemia Type 2 (CTLN2). Is adult onset, and ASS
deﬁciency is limited to the liver [2]. Patients with Type
2 disease usually present between the ages of 20 to 50
years although patients younger or much older than this
have also been reported. Type 2 disease is believed to be
caused by mutations in the gene (SLC25A13) which encodes
citrin, a mitochondrial aspartate glutamate carrier protein
(AGC2), located on chromosome 7q21 [3, 4]. Most reports
of Type 2 disease have been from Japan, where the incidence
is described to be 1 in 100,000 [3]. Individuals from
other countries with mutations diﬀerent from the common
Japanese mutationshavebeenidentiﬁedsuchasIsrael,North
America,UnitedKingdom,CzechRepublic,andPakistan[5–
10]. Patients are described to be thin, with up to 40% having
a body mass index under 17 and tend to have a predilection
for protein-rich foods [11]. Liver dysfunction is minimal
or absent. Most patients present suddenly with hyperam-
monemia and associated neuropsychiatric symptoms such as
altered conscious levels, irritability, seizures, or coma. A link
betweenType2diseaseandchronicpancreatitishasalsobeen
described [12–14].Cerebraloedema is the commonest mode
of death and usually occurs several years after onset.
Management of the disease involves strategies to remove
ammonia, maintenance of nitrogen excretion, reducing the
frequency of intercurrent episodes and nutritional and ﬂuid
repletion. Althoughpatients with urea cycledefects are com-
monly treated with low protein-high carbohydrate diets,Journal of Transplantation 3
this is harmful in patients with Type 2 citrullinaemia. High
carbohydrate intake increases NADH production, further
disrupting the urea cycle and stimulating the citrate-malate
shuttle, resulting in further hyperammonemia, hypertriglyc-
eridaemia, and fatty liver disease [15–18].
Presently, only LT is curative of the disorder [19, 20].
Withsuccessful LT,hyperammonemic episodes cease,dietary
restrictions are not required, and alternative pathway medi-
cation can be discontinued [21–26]. Successful LT for Type
2 disease has been reported with both deceased donor and
living donor grafts. Auxiliary partial orthotopic LT has also
been described for the treatment of urea cycle defects. Such
transplants using a left lobe graft have been described to
provide suﬃcient enzyme supplementation and can correct
citrullinaemia [27]. However, this technique too has its
complications, such as competition of blood inﬂow between
the native liver remnant and the graft and higher morbidity
rates compared to nonauxiliary transplanted recipients [28,
29]. Unlike in Type 1 disease, the metabolic correction of
type 2 disease with liver transplantation is complete, as the
enzyme deﬁciency is limited to the liver. Optimum timing
f o rL Ti su n k n o w na l t h o u g ht h ea i mi st oc o r r e c tt h e
underlying metabolic error before irreversible brain damage
occurs. Ikeda et al. reported that 1 of 7 citrullinemia Type 2
patients who underwent living-related liver transplantation
in their series continued to be cognitively impaired despite
transplantation, whereas the rest had recovered completely
from their neuropsychiatric symptoms [30]. This patient
had CT and MRI evidence of diﬀuse cortical atrophy of the
brain and marked decreased radionuclide uptake on brain-
spectroscopy images. A review based on worldwide data
of LT for urea cycle disorders suggested that neurological
impairments were more likelyto persist after LT in paediatric
ratherthanadultpatientsandinpatientsreceivingadeceased
donor graft rather than a living donor graft [25]. Some
authors advocate consideration for transplantation as soon
as the ﬁrst presentation of metabolic decompensation [9].
The true incidence of urea cycle defects is not known as
the disorder is commonly missed. The presentation of neo-
nates or infants is nonspeciﬁc and most paediatric patients
are evaluated for sepsis or respiratory disorders instead [19].
Unless speciﬁcally tested for, hyperammonaemia and an
evaluation for its cause may be missed in the diagnosis. The
same is true in adults. This has speciﬁc implications for
liver transplantation. Firstly, organs from deceased donors
should not be accepted if the aetiology of the cause of
death is vague. Plochl et al. reported an unfortunate patient
who developed acute hyperammoanemic encephalopathy
and died after receiving a liver from a male donor who had
died of atraumatic cerebral oedema of unknown cause [31].
Ornithine transcarbamylase deﬁciency was subsequently
diagnosed from the measurement of urea cycle enzymes
and molecular analysis of donor liver tissue. The maternal
uncle of this donor had also died from coma of unknown
cause. To ourknowledge, no such incidenthas beenreported
of a deceased liver donor with undiagnosed citrullinaemia
although it would be logical to assume that the same
poor outcome could happen in such a situation. Secondly,
deceased donor grafts are scarce in many parts of the world,
necessitating living donor liver transplantation instead. As
living donor grafts are usually harvested from relatives, a
thorough donor workup should be undertaken to exclude
an ASS deﬁciency state in the donor, since this is an
inheritable disorder. Apart from measuring plasma citrulline
and ammonia levels, some centres also biopsy donor liver
tissue to measure urea cycle enzymatic activity [25, 30]. In
the series by Morioka et al., parent donors were accepted if
their plasma ammonia levels and quantitative serum amino
acid analyses were normal despite their heterozygosity for
CTLN2 [25]. However, a sibling donor was further evaluated
with a liver biopsy and hepatic enzymes were assayed despite
normal plasma ammonia and quantitative serum amino
acid analysis in view of the nature of inheritance of this
disorder. Based on hepatic enzyme assay, this sibling donor
waseitherheterozygoteorlatentlydiseased.However,inview
of the need for an emergent transplant and his being the
only available donor, a left liver auxiliary partial orthotopic
transplant was performed with informed consent. Both
donor and recipient remained well beyond 77 months from
liver transplantation. The use of asymptomatic heterozygote
donors has not been reported to be associated with any
signiﬁcant morbidity or mortality thusfar althoughtheir use
is yet to be validated or established.
Hepatocyte transplants and gene transfers have been
explored for the treatment of urea cycle defects, including
citrullinaemia. However, these are not without risks, and
their current role remains in a research setting.
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